Table 2 HLA class I and class II typing
HLA class IHLA class II
HLA alleleHC (n (%))†MS (n (%))†HLA alleleHC (n (%))MS (n (%))
A*019 (26.5)6 (17.6)DRB1*017 (20.6)7 (20.6)
A*0216 (47.1)11 (32.4)DRB1*1512 (35.3)18 (52.9)
A*0310 (29.4)11 (32.4)DRB1*160 (0.0)2 (5.9)
A*114 (11.8)7 (20.6)DRB1*039 (26.5)7 (20.6)
A*235 (14.7)1 (2.9)DRB1*0413 (38.2)6 (17.6)
A*242 (5.9)6 (17.6)DRB1*115 (14.7)3 (8.8)
A*252 (5.9)2 (5.9)DRB1*121 (2.9)2 (5.9)
A*261 (2.9)0 (0.0)DRB1*137 (20.6)5 (14.7)
A*292 (5.9)0 (0.0)DRB1*142 (5.9)0 (0.0)
A*301 (2.9)1 (2.9)DRB1*078 (23.5)6 (17.6)
A*310 (0.0)3 (8.8)DRB1*082 (5.9)2 (5.9)
A*322 (5.9)3 (8.8)DRB1*090 (0.0)0 (0.0)
A*331 (2.9)1 (2.9)DRB1*101 (2.9)2 (5.9)
A*360 (0.0)2 (5.9)
A*681 (2.9)2 (5.9)DQA1*0126 (76.5)28 (82.4)
A*741 (2.9)0 (0.0)DQA1*028 (23.5)7 (20.6)
A*921 (2.9)0 (0.0)DQA1*0314 (41.2)6 (17.6)
DQA1*042 (5.9)3 (8.8)
B*077 (20.6)14 (41.2)DQA1*0514 (41.2)11 (32.4)
B*087 (20.6)6 (17.6)
B*134 (11.8)3 (8.8)DQB1*0215 (44.1)11 (32.4)
B*144 (11.8)2 (5.9)DQB1*0317 (50.0)13 (38.2)
B*154 (11.8)2 (5.9)DQB1*041 (2.9)2 (5.9)
B*182 (5.9)4 (11.8)DQB1*0510 (29.4)11 (32.4)
B*272 (5.9)1 (2.9)DQB1*0618 (52.9)21 (61.8)
B*354 (11.8)8 (23.5)
B*372 (5.9)1 (2.9)
B*381 (2.9)1 (2.9)
B*391 (2.9)4 (11.8)
B*404 (11.8)4 (11.8)
B*4412 (35.3)6 (17.6)
B*492 (5.9)0 (0.0)
B*514 (11.8)1 (2.9)
B*521 (2.9)1 (2.9)
B*530 (0.0)1 (2.9)
B*552 (5.9)2 (5.9)
B*571 (2.9)4 (11.8)
  • †Number (%) of subjects carrying each allele, either heterozygously or homozygously.

  • HC, 34 healthy control subjects; MS, 34 patients with multiple sclerosis.